ASK REDCHAT ANYTHING ABOUT 4D MOLECULAR THERAPEUTICS, INC.
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT)
Listen to this Section
$9.02
+0.1860
(
+2.11% )
313.4K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| 4D-150DetailsDiabetic macular edema |
Phase 2 |
| 4D-310DetailsFabry disease |
Phase 1/2 |
| 4D-710DetailsCystic fibrosis |
Phase 1/2 |
| 4D-125DetailsX-linked retinitis pigmentosa |
Phase 1/2 |
| 4D-150DetailsWet age-related macular degeneration |
Phase 1/2 |
| 4D-110DetailsChoroideremia |
Phase 1 |
| 4D-175DetailsGeographic atrophy |
Phase 1 |
Market Data
|
| Open |
$9.02 |
| Previous Close |
$8.84 |
| Volume |
313.4K |
| Market Cap |
$461.86M |
| Day Range |
$8.62 - $9.38 |
| 52 Week Range |
$3.68 - $12.34 |
| Shares Outstanding |
52.28M |
| Change % |
+2.11% |
| Net Change |
▲ 0.1860 |
| Insider Ownership |
-0.36% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Year | 2020 |
| Country | United States |
| Underwriter | IPO Intelligence Only |
Insider Ownership Transactions
Total Amount Purchased:
-58,662.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2024-02-29 |
Sale |
-1909.00 |
Bizily Scott |
SEC Filings
| Form Type |
Description |
Pages |
Date |
| 10-q |
Quarterly Reports |
92 |
Nov 10, 2025 |
| 8-k |
8K-related |
12 |
Nov 10, 2025 |
| 8-k |
8K-related |
17 |
Nov 07, 2025 |
| 8-k |
8K-related |
12 |
Nov 06, 2025 |
| 8-k |
8K-related |
12 |
Oct 31, 2025 |
| 4 |
Insider transactions |
1 |
Oct 27, 2025 |
| 4 |
Insider transactions |
1 |
Oct 20, 2025 |
| 4 |
Insider transactions |
1 |
Oct 14, 2025 |
| 3 |
Insider transactions |
1 |
Oct 10, 2025 |
| 8-k |
8K-related |
11 |
Oct 02, 2025 |